Daewoong Past Earnings Performance
Past criteria checks 2/6
Daewoong has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 7.9% per year. Daewoong's return on equity is 9.6%, and it has net margins of 6.6%.
Key information
18.2%
Earnings growth rate
18.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 7.9% |
| Return on equity | 9.6% |
| Net Margin | 6.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That Daewoong (KRX:003090) Is Using Debt Extensively
Nov 11
Daewoong Co., Ltd. (KRX:003090) Held Back By Insufficient Growth Even After Shares Climb 26%
Sep 01Daewoong Co., Ltd.'s (KRX:003090) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jul 14Is Daewoong (KRX:003090) Using Too Much Debt?
Jul 04Does Daewoong (KRX:003090) Have A Healthy Balance Sheet?
Apr 02With EPS Growth And More, Daewoong (KRX:003090) Is Interesting
Apr 13A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)
Mar 29Daewoong Co., Ltd. (KRX:003090) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Mar 14Daewoong (KRX:003090) Seems To Use Debt Quite Sensibly
Feb 21The Daewoong (KRX:003090) Share Price Has Soared 308%, Delighting Many Shareholders
Jan 31
Do Its Financials Have Any Role To Play In Driving Daewoong Co., Ltd.'s (KRX:003090) Stock Up Recently?
Dec 04Revenue & Expenses Breakdown
How Daewoong makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,880,071 | 123,360 | 571,799 | 176,459 |
| 30 Jun 24 | 1,825,714 | 118,195 | 553,511 | 178,268 |
| 31 Mar 24 | 1,821,844 | 135,340 | 556,384 | 174,025 |
| 31 Dec 23 | 1,813,841 | 152,665 | 545,492 | 176,599 |
| 30 Sep 23 | 1,811,723 | 123,049 | 1,277,149 | 86,522 |
| 30 Jun 23 | 1,783,012 | 122,647 | 1,026,003 | 114,576 |
| 31 Mar 23 | 1,735,656 | 117,547 | 523,653 | 174,207 |
| 31 Dec 22 | 1,697,338 | 102,566 | 508,915 | 169,887 |
| 30 Sep 22 | 1,657,478 | 124,723 | 494,921 | 154,728 |
| 30 Jun 22 | 1,600,944 | 112,646 | 466,976 | 146,440 |
| 31 Mar 22 | 1,560,377 | 99,018 | 450,442 | 140,967 |
| 31 Dec 21 | 1,511,374 | 78,730 | 431,966 | 134,260 |
| 30 Sep 21 | 1,451,197 | 105,593 | 406,842 | 131,571 |
| 30 Jun 21 | 1,428,068 | 94,024 | 399,184 | 131,845 |
| 31 Mar 21 | 1,375,581 | 86,028 | 388,795 | 126,820 |
| 31 Dec 20 | 1,355,337 | 98,379 | 395,876 | 118,851 |
| 30 Sep 20 | 1,362,729 | 49,531 | 398,011 | 121,791 |
| 30 Jun 20 | 1,343,957 | 45,569 | 408,601 | 117,515 |
| 31 Mar 20 | 1,375,384 | 65,058 | 404,966 | 119,113 |
| 31 Dec 19 | 1,365,679 | 61,493 | 388,752 | 123,955 |
| 30 Sep 19 | 1,339,502 | 41,771 | 367,893 | 221,824 |
| 30 Jun 19 | 1,313,898 | 44,530 | 340,753 | 193,494 |
| 31 Mar 19 | 1,261,879 | 27,355 | 324,180 | 128,659 |
| 31 Dec 18 | 1,231,290 | 29,863 | 311,280 | 130,618 |
| 30 Sep 18 | 1,186,059 | 68,359 | 306,704 | 29,483 |
| 30 Jun 18 | 1,171,372 | 68,406 | 304,562 | 62,989 |
| 31 Mar 18 | 1,149,164 | 67,927 | 297,593 | 128,220 |
| 31 Dec 17 | 1,123,957 | 66,251 | 296,164 | 120,546 |
| 30 Sep 17 | 1,113,711 | 53,527 | -124,649 | 123,106 |
| 30 Jun 17 | 1,076,124 | 49,187 | 8,680 | 116,986 |
| 31 Mar 17 | 1,036,113 | 34,188 | 272,908 | 110,977 |
| 31 Dec 16 | 1,014,966 | 19,831 | 269,777 | 112,694 |
| 30 Sep 16 | 996,885 | 10,688 | 679,958 | 101,229 |
| 30 Jun 16 | 1,002,592 | 11,074 | 537,782 | 82,801 |
| 31 Mar 16 | 997,332 | 25,784 | 260,646 | 62,137 |
| 31 Dec 15 | 996,757 | 38,623 | 253,165 | 40,865 |
| 30 Sep 15 | 978,600 | 35,386 | 252,068 | 29,911 |
| 30 Jun 15 | 945,037 | 26,648 | 248,920 | 26,886 |
| 31 Mar 15 | 925,511 | 24,480 | 123,808 | 28,020 |
| 31 Dec 14 | 893,953 | 23,811 | 241,889 | 27,461 |
| 30 Sep 14 | 879,699 | 25,540 | 257,930 | 26,177 |
| 30 Jun 14 | 866,072 | 36,765 | 251,236 | 26,574 |
| 31 Mar 14 | 848,551 | 41,186 | 366,683 | 26,759 |
| 31 Dec 13 | 843,315 | 40,772 | 247,976 | 29,465 |
Quality Earnings: A003090 has high quality earnings.
Growing Profit Margin: A003090's current net profit margins (6.6%) are lower than last year (6.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A003090's earnings have grown by 18.2% per year over the past 5 years.
Accelerating Growth: A003090's earnings growth over the past year (0.3%) is below its 5-year average (18.2% per year).
Earnings vs Industry: A003090 earnings growth over the past year (0.3%) did not outperform the Pharmaceuticals industry 22%.
Return on Equity
High ROE: A003090's Return on Equity (9.6%) is considered low.